Cantor starts Y-mAbs with Overweight on pivot to radiopharmaceuticals

Cantor Fitzgerald initiated coverage of Y-mAbs Therapeutics with an Overweight rating and $20 price target. Y-mAbs is a commercial stage company developing a “transformative” approach to radiopharmaceuticals, the analyst tells investors in a research note. The firm says that after a recent restructuring and pivoting to radioimmunotherapy, Y-mAbs appears to be well positioned to capture the emerging opportunity in radiopharmaceuticals, “a space that has attracted much strategic interest.” Cantor’s Overweight rating is based on the potential of the company’s pre-targeting radioimmunotherapy platform, that it believes offers several advantages over conventional one-step radiopharmaceuticals.